Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 257Carcinoma, Intraductal, Noninfiltrating 24Breast Carcinoma In Situ 21Neoplasms 12Neoplasm Metastasis 12Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Prostatic Neoplasms 5Endometrial Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Medulloblastoma 2Liver Neoplasms 2Infertility 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Melanoma × Tamoxifen × Clear all
NCT00492505 2014-01-10

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

National Cancer Institute (NCI)

Phase 2 Unknown
200 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡